Drugs from China are reshaping biotech. Track the licensing deals here.

Bristol Myers’ alliance with Hengrui ranks as the second-largest licensing pact of its kind since the start of 2025, trailing only AstraZeneca’s $18.5 billion tie-up with CSPC in January, according to BioPharma Dive data.

Raccontata dabiopharmadive.com